Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: Dominance of CYP 2C19 and 3A4

Journal of Clinical Pharmacology

Volumn 38, Issue 2, 1998, Pages 112-121

  Venkatakrishnan, Karthik ^a   Greenblatt, David J ^a   Von Moltke, Lisa L ^a,b   Schmider, Jürgen ^a,c   Harmatz, Jerold S ^a   Shader, Richard I ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b National Institutes of Mental Health

^c Merck Sharp Dohme Intl F

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA NAPHTHOFLAVONE; AMITRIPTYLINE; CYTOCHROME P450; KETOCONAZOLE; N DEMETHYLASE; NORTRIPTYLINE; OMEPRAZOLE; QUINIDINE; SULFAPHENAZOLE;

ANXIETY; ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DEPRESSION; DRUG METABOLISM; ENZYME MECHANISM; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER MICROSOME; LYMPHOBLASTOID CELL; MICHAELIS CONSTANT;

EID: 0031908744     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1998.tb04399.x     Document Type: Article

References (24)

1. Olesen OV, Linnet K: Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA expressed human scytochrome P-450 isozymes. Drug Metab Dispos 1997;25:740-744.
2. Rudorfer MV, Potter WZ: The role of metabolites of antidepressants in the treatment of depression. CNS Drugs 1997;7:273-312.
3. Woolhouse NM, Adjepon-Yamoah KK, Mellström B, Hedman A, Bertilsson L, Sjöqvist F: Nortriptyline and debrisoquine hydroxylations in Ghanaian and Swedish subjects. Clin Pharmacol Ther 1984;36:374-378.
4. Baumann P, Jonzier-Perey M, Koeb L, Kupfer A, Tinguely D, Schopf J: Amitriptyline pharmacokinetics and clinical response. II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin. Int Clin Psychopharmacol 1986;1:102-112.
5. Mellström B, Säwe J, Bertilsson L, Sjöqvist F: Amitriptyline metabolism: association with debrisoquine hydroxylation in non-smokers. Clin Pharmacol Ther 1986;39:369-371.
6. Nordin C, Sewers B, Bernitez J, Bertilsson L: Plasma concentrations of nortriptyline and its 10-hydroxy metabolite in depressed patients: relationship to the debrisoquine hydroxylation metabolic ratio. Br J Clin Pharmacol 1986;19:832-835.
7. Breyer-Pfaff U, Pfandl B, Nill K, Nusser E, Monney C, Jonzier-Perrey M et al: Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 enzymes. Clin Pharmacol Ther 1992;52:350-358.
8. Schmider J, Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI: N-demethylation of amitriptyline in vitro: role of cytochrome P-450 3A (CYP3A) isoforms and effect of metabolic inhibitors. J Pharmacol Exp Ther 1995;275:592-597.
9. Schmider J, Greenblatt DJ, Harmatz JS, Shader RI: Enzyme kinetic modelling as a tool to analyse the behaviour of cytochrome P-450 catalysed reactions: application to amitriptyline N-demethylation. Br J Clin Pharmacol 1996;41:593-604.
10. Ghahramani S, Ellis SW, Lennard MS, Ramsay LE, Tucker GT. Cytochromes P450 mediating the N-demethylation of amitriptyline. Br J Clin Pharmacol 1997;43:137-144.
11. Mellström B, Bertilsson L, Lou Y-C, Säwe J, Sjöqvist F: Amitriptyline metabolism: relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther 1983;34:516-520.
12. Brøsen K, Gram LF, Sorensen: Extremely slow metabolism of amitriptyline but normal metabolism of imipramine and desipramine in an extensive metabolizer of sparteine, debrisoquine and mephenytoin. Ther Drug Monit 1991;13:177-182.
13. Coutts RT, Bach MV, Baker GB: Metabolism of amitriptyline with CYP 2D6 expressed in a human cell line. Xenobiotica 1997;27:33-47.
14. von Moltke LL, Greenblatt DJ, Harmatz JS, Shader RI: Alprazolam metabolism in vitro: studies of human, monkey, mouse, and rat liver microsomes. Pharmacology 1993;47:268-276.
15. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Duan SX, Harmatz JS, Shader RI: Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interaction in vivo. J Pharmacol Exp Ther 1994;268:1278-1283.
16. Crespi CL: Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research. Adv Drug Res 1995;26:179-235.
17. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan KS, Raucy JL, et al: Evidence that CYP 2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 1994; 33:1743-1752.
18. Schmider J, Greenblatt DJ, von Moltke LL, Harmatz JS, Duan SX, Karsov D, Shader RI: Characterization of six in vitro reactions mediated by human cytochrome P450: application to the testing of cytochrome P450 directed antibodies. Pharmacology 1996; 52:125-134.
19. Yamaoka K, Nakagawa T, Uno T: Application of Akaike's information criterion in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1978;6:165-175.
20. Shimada T, Yamazaki S, Mimura M, Inui Y, Guengerich FP: Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-423.
21. von Moltke LL, Greenblatt DJ, Schmider J, Wright CE, Harmatz JS, Shader RI: In vitro approaches to predicting drug interactions in vivo. Biochem Pharmacol 1998;55:113-122.
22. Schulz P, Dick P, Blaschke TF, Hollister L: Discrepancies between pharmacokinetic studies of amitriptyline. Clin Pharmacokinet 1985;10:257-268.
23. Ko J-W, Sukhowa N, Thacker D, Chen P, Flockhart DA: Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos 1997;25:853-862.
24. Oleson OV, Linnet K: Metabolism of the tricyclic antidepressant amitriptyline by cDNA-expressed human cytochrome P450 enzymes. Pharmacology 1997;55:235-243.